​who ​int/​malaria/​publications/​world_​malaria_​report_​2013/​e

​who.​int/​malaria/​publications/​world_​malaria_​report_​2013/​en/​] URL 2. Ridley RG: Medical need, scientific opportunity and the drive for antimalarial

drugs. Nature 2002,415(6872):686–693. 10.1038/415686a11832957CrossRefPubMed 3. Bannister LH, Hopkins JM, Fowler RE, Krishna S, Mitchell GH: A brief illustrated guide to the ultrastructure of Plasmodium 4EGI-1 cell line falciparum asexual blood stages. Parasitol Today 2000, 16:427–433. 10.1016/S0169-4758(00)01755-511006474CrossRefPubMed 4. Asahi H: Plasmodium falciparum : Chemically defined medium for continuous intraerythrocytic Tozasertib solubility dmso growth using lipids and recombinant albumin. Exp Parasitol 2009, 121:22–28. 10.1016/j.exppara.2008.09.00918851965CrossRefPubMed 5. Asahi H: Intraerythrocytic Plasmodium falciparum growth in serum-free medium with an emphasis on growth-promoting factors. In Malaria Parasites. Edited by: Okwa OO. Croatia: InTech, Rijeka; 2012:73–90. [ http://​www.​intechopen.​com/​books/​malaria-parasites]URL selleck compound 6. PlasmoDB. [ http://​plasmodb.​org/​plasmo/​]

7. Asahi H, Tolba MEM, Tanabe M, Ohmae H: Molecular factors that are associated with early developmental arrest of intraerythrocytic Plasmodium falciparum . Can J Microbiol 2013, 59:485–493. 10.1139/cjm-2013-016623826958CrossRefPubMed 8. Asahi H, Kanazawa T: Continuous cultivation of intraerythrocytic Plasmodium falciparum in a serum-free medium with the use of a growth-promoting factor. Parasitology 1994, 109:397–401. 10.1017/S00311820000806417800407CrossRefPubMed 9. Asahi H, Izumiyama S, Tolba ME, Kwansa-Bentum B: Plasmodium

falciparum : differing effects of non-esterified fatty acids and phospholipids on intraerythrocytic growth in serum-free medium. ADP ribosylation factor Exp Parasitol 2011, 127:708–713. 10.1016/j.exppara.2010.11.00121095186CrossRefPubMed 10. Alvarez HM, Xue Y, Robinson CD, Canalizo-Hernandez MA, Marvin RG, Kelly RA, Mondragon A, Penner-Hahn JE, O’Halloran TV: Tetrathiomolybdate inhibits copper trafficking proteins through metal cluster formation. Science 2010,327(5963):331–334. 10.1126/science.1179907365811519965379CrossRefPubMedCentralPubMed 11. Ding X, Xie H, Kang YJ: The significance of copper chelators in clinical and experimental application. J Nutr Biochem 2011, 22:301–310. 10.1016/j.jnutbio.2010.06.01021109416CrossRefPubMed 12. Festa RA, Thiele DJ: Copper: an essential metal in biology. Curr Biol 2011, 21:R877-R883. 10.1016/j.cub.2011.09.040371800422075424CrossRefPubMedCentralPubMed 13. Turski ML, Thiele DJ: New roles for copper metabolism in cell proliferation, signaling, and disease. J Biol Chem 2009, 284:717–721. 10.1074/jbc.R800055200261360418757361CrossRefPubMedCentralPubMed 14. Markossian KA, Kurganov BI: Copper chaperones, intracellular copper trafficking proteins. Function, structure, and mechanism of action. Biochemistry (Mosc) 2003, 68:827–837. 10.1023/A:102574022888812948382CrossRef 15. Choveaux DL, Przyborski JM, Goldring JP: A Plasmodium falciparum copper-binding membrane protein with copper transport motifs.

Comments are closed.